Washington D.C. – October 28, 2024 – Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced late-breaking data demonstrating significant benefit of the ...

Results were presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 in San Francisco on October 27, 2025 DynamX® bioadaptor is the first interventional technology to ...

Drug Eluting Stents (DES) are the mainstay of coronary artery disease treatment. Although DES design iterations have reduced MACE in the first year after PCI, beyond 1-year, a persistent 2-3% ...

Paris – May 21, 2025 – Elixir Medical, a developer of transformative technologies to treat cardiovascular and peripheral disease, today announced three-year results from the large 445-patient ...

Dubai, UAE: – Elixir Medical, a developer of breakthrough cardiovascular technologies with a strong presence in the Middle East market, today announced that the large international randomized ...

Once approved, the DynamX Coronary Bioadaptor System would become the first percutaneous coronary intervention (PCI) treatment available in Japan to demonstrate restoration of vessel motion and ...

MILPITAS, Calif.--(BUSINESS WIRE)--Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced print publication of a study in the latest issue of Cardiovascular ...

The DynamX Bioadaptor — arguably the most original concept in coronary stent design to come along in 3 decades — demonstrated excellent safety and efficacy in a 12-month international, ...

(MENAFN- GlobeNewsWire - Nasdaq) Elixir Medical's DynamX Bioadaptor Demonstrates Significant Improvement Over Contemporary Drug-Eluting Stent in Patients with Acute Coronary Syndrome and Complex ...

DynamX® bioadaptor is the first interventional technology to demonstrate significant benefit with a reduction in long term adverse events in two consecutive randomized controlled trials MILPITAS, ...

Paris, May 21, 2025 (GLOBE NEWSWIRE) -- -Sustained durability of treatment effect with significantly lower TLF rates (2.7% versus 7.2%, p=0.030) with DynamX ® compared to DES- -Significantly lower ...